Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2022

BPH (benign prostatic hyperplasia, BPH) is a common disease and frequently encountered disease in older men, main show is prostate of glands and stroma hyperplasia, prostate enlargement, lower urinary tract symptoms (the lower urinary tract symptom, LUTS), and bladder outlet obstruction.There are currently three major classes of drugs for BPH: 5-beta-reductase inhibitors, such as finasteride;Beta-blockers, such as terazosin hydrochloride, doxazosin mesylate, etc.Herbal preparations and Chinese medicine, such as the general, etc.
Due to the COVID-19 pandemic, the global Benign Prostatic Hyperplasia (BPH) Medication market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Benign Prostatic Hyperplasia (BPH) Medication market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Benign Prostatic Hyperplasia (BPH) Medication landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
5-Alpha-Reductase Inhibitors accounting for % of the Benign Prostatic Hyperplasia (BPH) Medication global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Benign Prostatic Hyperplasia (BPH) Medication include Astellas Pharma, Eli Lilly, GlaxoSmithKline, Sanofi, ADC Therapeutics, Bayer HealthCare, Bristol-Myers Squibb, Valeant Pharmaceuticals and Endo Pharmaceuticals, etc. In terms of revenue, the global 3 largest players have a % market share of Benign Prostatic Hyperplasia (BPH) Medication in 2021.
This report focuses on Benign Prostatic Hyperplasia (BPH) Medication volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Benign Prostatic Hyperplasia (BPH) Medication market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Benign Prostatic Hyperplasia (BPH) Medication Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Merck
Novartis
Advaxis
Teva Pharmaceutical Industries
Urologixs
Agennix
ANI Pharmaceuticals
BHR Pharma
Boehringer Ingelheim
Sanpower Group
Eisai
Ferring
IO THERAPEUTICS
LIDDS
Madrigal Pharmaceuticals
Nymox Pharmaceutical
Spectrum Pharmaceuticals
Takeda Pharmaceuticals

Frequently Asked Questions